Tonix Pharmaceuticals (NASDAQ:TNXP) Coverage Initiated at StockNews.com

StockNews.com began coverage on shares of Tonix Pharmaceuticals (NASDAQ:TNXP) in a report issued on Thursday morning. The firm issued a hold rating on the stock.

Tonix Pharmaceuticals Price Performance

TNXP opened at $0.26 on Thursday. The firm has a market cap of $47.84 million, a price-to-earnings ratio of 0.00 and a beta of 2.02. The company has a current ratio of 3.33, a quick ratio of 2.81 and a debt-to-equity ratio of 0.07. The stock’s 50-day moving average price is $0.25 and its 200 day moving average price is $0.33. Tonix Pharmaceuticals has a 12-month low of $0.12 and a 12-month high of $12.48.

Tonix Pharmaceuticals (NASDAQ:TNXP) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.23) EPS for the quarter, beating the consensus estimate of ($2.03) by $1.80. Tonix Pharmaceuticals had a negative net margin of 1,197.86% and a negative return on equity of 163.95%. The business had revenue of $2.82 million during the quarter, compared to analyst estimates of $2.63 million. As a group, sell-side analysts expect that Tonix Pharmaceuticals will post -17.63 earnings per share for the current year.

About Tonix Pharmaceuticals

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.